With the appointment of Dr. Vinay Prasad as the director of the FDA’s Center for Biologics Evaluation and Research (CBER), a fresh wave of optimism is sweeping through the rare disease community. Known for his previous criticisms of the FDA’s drug approval standards, Dr. Prasad’s current commitment to accelerate access to innovative therapeutics for rare […]
Category: Promise Bio
Promise Bio Secures $8.3M for Immune Diseases Platform
Riding the wave of investor confidence, Promise Bio has successfully secured a robust funding round of $8.3 million, a financial injection set to catapult their innovative platform targeting immune-mediated diseases into a new phase of development. This transformative funding will not only bolster Promise Bio’s cutting-edge technologies but also illuminate new horizons for potential therapies […]
